Maintaining Investments in New Innovation Act
United States118th CongressHR-5547House of Representatives
Updated: Dec 17, 2024
Summary
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Bill texts
All available records shown.
Timeline
Latest companion bill action
S-476: Maintaining Investments in New Innovation ActRead twice and referred to the Committee on Finance.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
House of Representatives
Introduced in House
Referred to the Subcommittee on Health.
House of Representatives
Referred to the Subcommittee on Health.
House of Representatives
All available records shown.